Form 483

Hanlim Pharm Co. Ltd. Form 483, 2026-04-24

FDA issued a Form 483 to Hanlim Pharm Co. Ltd. on 2026-04-24 with 11 public-safe observations.

483· Form 483 issuedHuman Drugs11 observations

Hanlim Pharm Co. Ltd. · Yongin, Korea (the Republic of) · Issued April 24, 2026

Overview

  • 11 public-safe observations are available for this inspection.
  • 10 structured CFR citations are represented.
  • 2 investigators are tied to this Form 483.

Inspectional observations

Each observation cites the regulation FDA found the firm out of compliance with.

24 Apr 2026
21 CFR 211.100(a)

Absence of Written Procedures

Cited by Justin A Boyd, Hung H Do

24 Apr 2026
21 CFR 211.113(b)

Procedures for sterile drug products

Cited by Justin A Boyd, Hung H Do

24 Apr 2026
21 CFR 211.113(b)

Validation lacking for sterile drug products

Cited by Justin A Boyd, Hung H Do

24 Apr 2026
21 CFR 211.160(a)

Following/documenting laboratory controls

Cited by Justin A Boyd, Hung H Do

24 Apr 2026
21 CFR 211.160(b)

Scientifically sound laboratory controls

Cited by Justin A Boyd, Hung H Do

Inspected site

HPHanlim Pharm Co. Ltd.Yongin, Korea (the Republic of)

Inspection team

Cited regulations

CFR citations associated with this Form 483.

CitationWhat it coversCited
21 CFR 211.113(b)Cited across public-safe Form 483 observations2x
21 CFR 211.100(a)Cited across public-safe Form 483 observations1x
21 CFR 211.160(a)Cited across public-safe Form 483 observations1x
21 CFR 211.160(b)Cited across public-safe Form 483 observations1x
21 CFR 211.166(a)Cited across public-safe Form 483 observations1x
21 CFR 211.22(d)Cited across public-safe Form 483 observations1x
21 CFR 211.42(c)Cited across public-safe Form 483 observations1x
21 CFR 211.42(c)(10)(iv)Cited across public-safe Form 483 observations1x
21 CFR 211.42(c)(10)(v)Cited across public-safe Form 483 observations1x
21 CFR 211.67(a)Cited across public-safe Form 483 observations1x

Full 483 report

Get the verbatim text of all 11 observations

The full inspection record, as Atlas holds it, so your team sees exactly what was cited and how it was answered.

  • The site's full inspection history around this Form 483
  • Whether these citations escalated to a warning letter
  • The investigators involved and the citations they repeat elsewhere